Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in Pediatric Solid/CNS Tumors and Recurrent LGG
NCT05222165Phase 2Withdrawn
- Sponsor
- Helsinn
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of infigratinib in solid tumor (advanced stage), central nervous system tumor, glioma, sponsored by Helsinn. Planned start Oct 2021; status: withdrawn.
02
Drugs
infigratinib
03
Conditions
solid tumor (advanced stage)central nervous system tumorglioma
Beyond the preview
Go deeper on NCT05222165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222165.